TickerFacts.

Compare

Cero Therapeutics Holdings, Inc. vs BioCardia, Inc. vs Estrella Immunopharma, Inc. vs Tevogen Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearCero Therapeutics Holdings, Inc.
CERO		BioCardia, Inc.
BCDA		Estrella Immunopharma, Inc.
ESLA		Tevogen Inc.
TVGN
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$0n/an/a
Revenue growth (YoY)n/a-100.0%n/an/a
Gross marginn/an/an/an/a
Operating marginn/an/an/an/a
Net marginn/an/an/an/a
Net income-$19.92M-$8.23M-$13.06M-$26.28M
EPS (Diluted)n/an/a-$0.35-$8.08
Operating cash flow-$16.10M-$7.44M-$1.79M-$12.33M
Free cash flown/a-$7.44Mn/a-$12.39M
Cash & equivalentsn/a$2.50M$1.38M$0
Total assets$3.64M$3.41M$3.18M$4.38M
Total liabilities$9.09M$2.52M$13.54M$12.62M
Shareholders' equity-$5.45M$895.0K-$10.37M-$8.23M
Return on year-end equityn/a-919.3%n/an/a
Shares outstandingn/a10.76Mn/a4.02M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearCero Therapeutics Holdings, Inc.BioCardia, Inc.Estrella Immunopharma, Inc.Tevogen Inc.
Latestn/a$0
Ended 2025-12-31		n/an/a
1 year earliern/a$58.0K
Ended 2024-12-31		n/an/a
2 years earliern/a$477.0K
Ended 2023-12-31		n/an/a
3 years earliern/a$1.35M
Ended 2022-12-31		n/an/a
4 years earliern/a$1.01M
Ended 2021-12-31		n/an/a